Calif. voters lean toward stem cell measure-pol
By Reuters,
Reuters
| 09. 24. 2004
LOS ANGELES, Sept 23 (Reuters) - A majority of likely voters in California favor a ballot proposal that would authorize $3 billion in state bonds to fund controversial stem cell research, according to a poll released on Thursday.
The referendum, on the Nov. 2 ballot, would create the largest pool of public funding for such research in the United States at a time when the Bush administration has sharply curtailed spending on studies involving embryonic stem cells.
Backers of the initiative, including Hollywood celebrities and Silicon Valley billionaires, argue that such research could potentially lead to cures for diseases such as Parkinson's, Alzheimer's and diabetes.
A survey by the Los Angeles Times showed that while most voters had not yet formed an opinion on the ballot measure known as Proposition 71, a majority expressed support once they were read the proposal itself.
The survey showed 54 percent of likely voters in California said they were inclined to vote for the stem cell proposal, compared with 32 percent who said they would vote against it.
Fourteen percent said they were not...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
